Lendman said that the event here in the Boston area had generated so much excitement among would-be employers and employees that he plans to repeat it in the San Francisco Bay Area this coming April
The South San Francisco, Calif., company (NASDAQ:CORR) raised $15 million in an intial public offering in June 1991, and another $36.5 million four months later
announced Wednesday at Hambrecht & Quist's 11th Annual Life Sciences Conference in San Francisco that it has initiated a Phase II clinical trial of its recombinant human ciliary neurotrophic factor (rhCNTF) in patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS
Speaking at Hambrecht & Quist's 11th Annual Life Sciences Conference in San Francisco, Telios (NASDAQ:TLIO) also announced the results of its recently completed multicenter clinical trials on TelioDerm, an adhesion peptide that acts as a provisional matrix to accelerate tissue regeneration, for treating chronic dermal ulcers...of South San Francisco, Calif., dating from 1991 to develop an anti-coagulant based on short peptides to block platelet aggregation
Sugen, which already has $15 million in the bank, will discuss this collaboration Wednesday at Hambrecht & Quist's 11th Annual Life Sciences Conference in San Francisco. -- Jennifer Van Brunt Senior Editor (c) 1997 American Health Consultants
By Lisa Piercey Business Editor The three-day 11th Annual Hambrecht & Quist Life Sciences Conference kicked off in San Francisco on Monday with more than 1,800 investors in attendance and standing room only crowds at many company presentations...Calgene CEO Refutes Article Calgene Inc.'s chief executive officer, Roger Salquist, used part of his time before investors Monday to criticize an article that appeared in Sunday's San Francisco Examiner
Genentech (NYSE:GNE), one of Xenova's strategic partners and an existing shareholder, invested $3.5 million in the offering, bringing the South San Francisco, Calif., company's total equity investment to date in Xenova to $10.3 million...Xenova will be making a presentation at the 11th Annual H&Q Life Sciences Conference in San Francisco on Tuesday. -- Jennifer Van Brunt Senior Editor (c) 1997 American Health Consultants
The rate of approval, however, may improve in the long term, according to G. Steven Burrill, national director of manufacturing and high technology industry services for Ernst & Young of San Francisco...ANALYSTS' PICKS FOR 1993 Kogenate Factor VIII:C Kogenate Factor VIII:C is the recombinant human blood clotting factor VIII made by South San Francisco, Calif.-based Genentech Inc.'s (NYSE:GNE) licensee, Miles Laboratories
TYPE B BOTULINUM TOXIN (AN-072) For treating cervical dystonia (involuntary muscle contraction) Athena Neurosciences Inc. (NASDAQ:ATHN), South San Francisco, Calif
Mark Edwards of Recombinant Capital, a consulting firm in San Francisco, said that biotechnology financing windows have historically been led by secondary offerings, not IPOs...The creative investment muscle has begun to flex again this fall," said G. Stephen Burrill, national director of manufacturing/high technology at Ernst & Young in San Francisco
Harry Hollander, an AIDS physician at the University of California, San Francisco, warned that the drug may have side effects such as drowsiness and muddled thinking, and should not be given to all patients
of South San Francisco, Calif., pursued this research with scientists from Lawrence Berkeley Laboratory and the University of Texas Southwestern Medical School in Dallas
The Santa Clara, Calif., company opened the first of these centers in South San Francisco in November 1992, as part of its ongoing AIDS therapy trials